Brief: Scandion And Alligator Bioscience Announce Positive Results From Collaboration

Alligator Bioscience AB

02/09/2021 08:53

Sept 2 (Reuters) - Scandion Oncology A/S  SCOLG.ST :
    * POSITIVE RESULTS FROM THE SCANDION ONCOLOGY A/S AND
ALLIGATOR
BIOSCIENCE AB COLLABORATION FURTHER SUPPORTS EFFICACY OF SCO-101
IN COMBINATION THERAPY
    * AFTER FINAL DATA HAS BEEN EVALUATED, JOINT FEASIBILITY
STUDY
HAVE REACHED ALL GOALS OF COOPERATION AND COMPANIES HAVE NOW
CONCLUDED COLLABORATION
    * DATA SUPPORT BASIC CONCEPT THAT SCO-101 IN COMBINATION
WITH
CHEMOTHERAPY AND IMMUNO-ONCOLOGY IS WELL TOLERATED AND HAS A
VERY POTENT ANTI-TUMOR EFFECT IN VIVO ON DRUG RESISTANT CANCER
CELLS
    * DATA FURTHER VALIDATE POTENTIAL OF MITAZALIMAB IN
COMBINATION
WITH STANDARD OF CARE CHEMOTHERAPY SUCH AS FOLFIRINOX.

Source text for Eikon:  ID:nWkr6BMLRW 
Further company coverage:  SCOLG.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))